Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ).
Shin Nippon Biomedical Laboratories reported consolidated results for the nine months ended December 31, 2025, showing revenue down 4.7% year-on-year to ¥21.2 billion and steep declines in operating profit (down 45.7%), ordinary profit (down 24.6%) and profit attributable to owners of parent (down 29.2%), with basic earnings per share falling to ¥54.54. Despite weaker earnings, the company’s equity ratio improved to 46.7% and net assets rose materially to ¥53.2 billion, supported by higher total assets, while it maintained its annual dividend forecast of ¥50 per share for the fiscal year ending March 31, 2026 and revised full-year guidance to lower revenue and profit, signaling a more challenging operating environment but continued commitment to shareholder returns.
The most recent analyst rating on (JP:2395) stock is a Buy with a Yen1802.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. is a Japan-based life sciences company listed on the Tokyo Stock Exchange Prime Market, providing contract research and related biomedical services. The group focuses on preclinical and other research support for pharmaceutical and biotech clients, positioning itself as a key player in outsourced drug development services in Japan and overseas.
Average Trading Volume: 285,930
Technical Sentiment Signal: Buy
Current Market Cap: Yen68.07B
For an in-depth examination of 2395 stock, go to TipRanks’ Overview page.